UCL Cancer Institute


Welcome to UCL Cancer Institute 

The UCL Cancer Institute is the hub for cancer research at University College London, one of the World's leading universities. The Institute draws together over 300 talented scientists who are working together to translate research discoveries into developing kinder, more effective therapies for cancer patients. If you are thinking about studying with us, applications to our flagship MSc Cancer postgraduate programme will open soon for September 2018 entry, plus new undergraduate degree BSc Cancer Biomedicine starting September 2018 is now open to application. 

News and features

First prostate cancer patient scanned using hyperpolarised MRI in Europe

A University College Hospital prostate cancer patient has undergone diagnosis using hyperpolarised Magnetic Resonance Imaging (MRI) as part of a UCL clinical trial. Led by Dr Shonit Punwani, the trial aims to develop more accurate and personalised treatment for cancer.

Published: Aug 23, 2017 4:17:30 PM

Existing drugs could benefit patients with bone cancer, genetic study suggests

A subgroup of patients with osteosarcoma - a form of bone cancer - could be helped by an existing drug, suggest scientists from the Wellcome Trust Sanger Institute and their collaborators at University College London Cancer Institute and the Royal National Orthopaedic Hospital NHS Trust.

Published: Jun 23, 2017 1:45:15 PM

New drug trial effective in shrinking cervical cancer tumours

A new drug trialled at the NIHR/Wellcome UCLH Clinical Research Facility (CRF) could help improve outcomes for women with advanced cervical cancer. More than a quarter the participants in trials of the immunotherapy drug Nivolumab experienced significant tumour shrinkage or complete remission. 

Published: Jun 16, 2017 6:54:00 PM

FOXFIRE combined analysis study results announced

Analysis from the FOXFIRE studies, led by Professor Ricky Sharma, indicates no benefit in overall survival from adding selective internal radiotherapy (SIRT) to first-line oxaliplatin-based chemotherapy for metastatic colorectal cancer.

Published: May 23, 2017 4:36:15 PM

Drug improves survival of patients with rare cancer by almost a quarter

Patients who take the chemotherapy drug, capecitabine, after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug, according to the results of a phase III clinical trial presented at the 2017 ASCO Annual Meeting in Chicago.

Published: May 23, 2017 4:36:15 PM

Cancer Research UK-UCL Centre

Cancer Research UK-UCL Centre

The Cancer Research UK-UCL Centre is a network and partnership between Cancer Research UK, UCL and UCL's associated Hospital Trusts. The Centre's mission is to facilitate collaboration to advance world-class translational cancer research.

Study with us

Study with us

Our education programmes reflect the depth and breadth of research expertise within the UCL Cancer Institute. Join our community of research scientists and academic clinicians through our postgraduate taught MSc Cancer or PhD studies.

Clinical Trials

Clinical Trials

The Cancer Research UK and UCL Cancer Trials Centre is one of the largest cancer trials centres in the UK. The CTC conducts multi-centre national and international phase III trials, feasibility studies and early phase I and II studies.

Our Research

Our Research

UCL is a world leader in interdisciplinary research. The UCL Cancer Institute is uniquely placed to leverage this multidisciplinary approach to advance discoveries in basic, translational and clinical cancer research.


Crick International Cancer Conference

Bringing together leading cancer scientists from all over the world the 1st Crick Cancer Conference  will take place September 2017.

Starts: Sep 24, 2017 4:45:00 PM

Support our work

GCLP lab

Help us to continue the research that will lead to the breakthroughs in therapies for cancer patients. Support us >

Action for equality and diversity 

Athena SWAN Silver Award

UCL Cancer Institute is proud to hold an Athena SWAN silver award in recognition of our commitment to advancing equality, diversity and inclusion. 

Learn more about Athena SWAN initiatives >

Connect with us